-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Gliomas are primary brain tumors with diverse clinical manifestations, and approximately 100,000 people worldwide are diagnosed with gliomas each year
.
Glioblastoma, the most common type of primary brain tumor, is particularly aggressive, with a median overall survival (OS) of only about 15-18 months after standard therapy
About 8% of gliomas diagnosed carry fibroblast growth factor receptor (FGFR) genomic variants (amplifications, mutations, and/or fusions), particularly EGFR1 and EGFR2
Adult patients with relapsed or progressive gliomas with clear EGFR mutations were recruited to receive oral infigratinib 125 mg (1-21/28 days)
.
The primary endpoint was investigator-assessed 6-month progression-free survival (PFS)
treatment effect
treatment effect
treatment effect
A total of 26 patients were recruited, the 6-month progression-free survival rate was 16%, the median progression-free survival was 1.
7 months, and the objective response rate was 3.
8%
The 6-month progression-free survival rate was 16%, the median progression-free survival was 1.
The FGFR inhibitor infigratinib monotherapy has limited efficacy in patients with recurrent glioma with EGFR mutations, but patients with FGFR1 or FGFR3 point mutations and FGFR3-TACC3 fusion variants have durable disease from infigratinib monotherapy Controlled FGFR inhibitor infigratinib monotherapy has limited efficacy in patients with recurrent gliomas with EGFR mutations, but patients with FGFR1 or FGFR3 point mutations and FGFR3-TACC3 fusion variants have durable infigratinib monotherapy disease control
Original source:
Original Source: Original Source:Lassman Andrew B, Sepúlveda-Sánchez Juan Manuel, Cloughesy Timothy et al.
Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II Study.
[J] .
Clin Cancer Res, 2022, https://doi.
Lassman Andrew B, Sepúlveda-Sánchez Juan Manuel, Cloughesy Timothy et al.
Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II Study.
[J] .
Clin Cancer Res, 2022, https://doi.
org/10.
1158 /1078-0432.
CCR-21-2664.
Leave a message here
